Literature DB >> 19898928

BAK, BAX, and NBK/BIK proapoptotic gene alterations in Iranian patients with ataxia telangiectasia.

Anna Isaian1, Natalia V Bogdanova, Masoud Houshmand, Masoud Movahadi, Asghar Aghamohammadi, Asghar Agamohammadi, Nima Rezaei, Lida Atarod, Mahnaz Sadeghi-Shabestari, Seyed Hasan Tonekaboni, Zahra Chavoshzadeh, Seyed Mohammad Seyed Hassani, Reza Mirfakhrai, Taher Cheraghi, Najmoddin Kalantari, Mitra Ataei, Thilo Dork-Bousset, Mohammad Hossein Sanati.   

Abstract

INTRODUCTION: Ataxia telangiectasia (AT) is an autosomal recessive multisystem disorder characterized by variable immunodeficiency, progressive neurodegeneration, occulocutaneous telangiectasia, and an increased susceptibility to malignancies. This study was designed to study the role of proapoptotic BAK, BAX, and NBK/BIK genes in a group of patients with AT to elucidate the possible role of these genes in progression of malignancies in this disease.
MATERIALS AND METHODS: Fifty Iranian patients with AT were investigated in this study. The entire coding regions of the BAK gene (exons 2-6), NBK/BIK gene (exons 2-5), and BAX gene (exons 1-7) were amplified using polymerase chain reaction (PCR). The PCR products were separated by 2% agarose gel electrophoresis, and all positive samples were verified by direct sequencing of PCR products using the same primers used for PCR amplification, BigDye chemistry, and Avent 3100 Genetic Analyzer following the manufacturer's instructions (Applied Biosystems).
RESULTS: Eight of fifty Iranian AT patients (16%) exhibited a C > T transition in exon 2 (c342C > T) of the BAK gene, while none of the healthy controls had such alteration (P = 0.0001). Higher frequency of another nucleotide substitution in the noncoding region of exon 7 in BAX gene (6855G > A) was also identified in 68% of the patient group versus 24% in the controls (P < 0.0001). Sequence alteration in intronic region of the NBK/BIK gene IVS4-12delTC was observed in 52% of AT patients, which was significantly higher than 20% in the control group (P = 0.0023). Another variant IVS1146C > T in the intronic region of the BAX gene was found in 78% of patients, which was significantly higher than 10% in the controls (P < 0.0001). Frequency of alteration in intronic region of exon 3 of the BAX gene (IVS3 + 14A > G) was also significantly higher in the AT patients (P < 0.0001). DISCUSSION: Several alterations in the proapoptotic genes BAK, NBK/BIK, and BAX were found in our study, which could elucidate involvement of the mitochondrial pathway mediated apoptosis in accelerating and developing of cancers and in immunopathogenesis of AT. Such altered apoptosis in AT could play some roles in developing cancers in this group of patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19898928     DOI: 10.1007/s10875-009-9340-6

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  24 in total

Review 1.  The expanding role of mitochondria in apoptosis.

Authors:  X Wang
Journal:  Genes Dev       Date:  2001-11-15       Impact factor: 11.361

2.  Mutations of the BAK gene are infrequent in advanced gastric adenocarcinomas in Koreans.

Authors:  Sang-Pyo Kim; Mi-Sun Hwang; Young Rok Cho; Sun Young Kwon; Yu-Na Kang; In-Ho Kim; Soo-Sang Sohn; Kyo-Cheol Mun; Taeg-Kyu Kwon; Seong-Ryong Lee; Seong-Il Suh
Journal:  Cancer Lett       Date:  2003-05-30       Impact factor: 8.679

3.  Infrequent bax gene mutations in B-cell lymphomas.

Authors:  H Peng; A Aiello; G Packham; P G Isaacson; L Pan
Journal:  J Pathol       Date:  1998-12       Impact factor: 7.996

4.  Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype.

Authors:  N Rampino; H Yamamoto; Y Ionov; Y Li; H Sawai; J C Reed; M Perucho
Journal:  Science       Date:  1997-02-14       Impact factor: 47.728

Review 5.  Ataxia-telangiectasia: diagnosis and treatment.

Authors:  Susan Perlman; Sara Becker-Catania; Richard A Gatti
Journal:  Semin Pediatr Neurol       Date:  2003-09       Impact factor: 1.636

6.  Mutations of the BIK gene in human peripheral B-cell lymphomas.

Authors:  Vincenzo Arena; Maurizio Martini; Myriam Luongo; Arnaldo Capelli; Luigi Maria Larocca
Journal:  Genes Chromosomes Cancer       Date:  2003-09       Impact factor: 5.006

Review 7.  Apoptosis pathways and oncolytic adenoviral vectors: promising targets and tools to overcome therapy resistance of malignant melanoma.

Authors:  Jürgen Eberle; Lothar F Fecker; Amir M Hossini; Bahtier M Kurbanov; Henry Fechner
Journal:  Exp Dermatol       Date:  2008-01       Impact factor: 3.960

8.  Expression and function of bcl-2 proteins in melanoma.

Authors:  Jürgen Eberle; Amir M Hossini
Journal:  Curr Genomics       Date:  2008-09       Impact factor: 2.236

9.  A molecular analysis by gene expression profiling reveals Bik/NBK overexpression in sporadic breast tumor samples of Mexican females.

Authors:  Normand García; Fabio Salamanca; Horacio Astudillo-de la Vega; Everardo Curiel-Quesada; Isabel Alvarado; Rosenda Peñaloza; Diego Arenas
Journal:  BMC Cancer       Date:  2005-08-01       Impact factor: 4.430

10.  Genetic alterations in the coding region of the bak gene in uterine cervical carcinoma.

Authors:  K M Y Wani; N G Huilgol; T Hongyo; K Shah; N Chatterjee; C K K Nair; T Nomura
Journal:  Br J Cancer       Date:  2003-05-19       Impact factor: 7.640

View more
  3 in total

1.  History of primary immunodeficiency diseases in iran.

Authors:  Asghar Aghamohammadi; Mostafa Moin; Nima Rezaei
Journal:  Iran J Pediatr       Date:  2010-03       Impact factor: 0.364

2.  Investigation of tRNA and ATPase 6/8 gene mutations in Iranian ataxia telangiectasia patients.

Authors:  Massoud Houshmand; Sadaf Kasraie; Solmaz Etemad Ahari; Mostafa Moin; Mohammadali Bahar; Akram Zamani
Journal:  Arch Med Sci       Date:  2011-07-11       Impact factor: 3.318

3.  The natural history of ataxia-telangiectasia (A-T): A systematic review.

Authors:  Emily Petley; Alexander Yule; Shaun Alexander; Shalini Ojha; William P Whitehouse
Journal:  PLoS One       Date:  2022-03-15       Impact factor: 3.752

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.